|
1
|
Lam MP and Cheung BM: The pharmacogenetics
of the response to warfarin in Chinese. Br J Clin Pharmacol.
73:340–347. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Takahashi H and Echizen H:
Pharmacogenetics of warfarin elimination and its clinical
implications. Clin Pharmacokinet. 40:587–603. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vecsler M, Loebstein R, Almog S, Kurnik D,
Goldman B, Halkin H and Gak E: Combined genetic profiles of
components and regulators of the vitamin K-dependent
gamma-carboxylation system affect individual sensitivity to
warfarin. Thromb Haemost. 95:205–211. 2006.PubMed/NCBI
|
|
4
|
Li S, Zou Y, Wang X, Huang X, Sun Y, Wang
Y, Dong L and Jiang H: Warfarin dosage response related
pharmacogenetics in Chinese population. PLoS One. 10:e01164632015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gage BF, Yan Y, Milligan PE, Waterman AD,
Culverhouse R, Rich MW and Radford MJ: Clinical classification
schemes for predicting hemorrhage: Results from the National
Registry of Atrial Fibrillation (NRAF). Am Heart J. 151:713–719.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pisters R, Lane DA, Nieuwlaat R, de Vos
CB, Crijns HJ and Lip GY: A novel user-friendly score (HAS-BLED) to
assess 1-year risk of major bleeding in patients with atrial
fibrillation: The euro heart survey. Chest. 138:1093–1100. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Self TH, Oliphant CS, Reaves AB,
Richardson AM and Sands CW: Fever as a risk factor for increased
response to vitamin K antagonists: A review of the evidence and
potential mechanisms. Thromb Res. 135:5–8. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Harada T, Ariyoshi N, Shimura H, Sato Y,
Yokoyama I, Takahashi K, Yamagata S, Imamaki M, Kobayashi Y, Ishii
I, et al: Application of Akaike information criterion to evaluate
warfarin dosing algorithm. Thromb Res. 126:183–190. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Holmes MV, Hunt BJ and Shearer MJ: The
role of dietary vitamin K in the management of oral vitamin K
antagonists. Blood Rev. 26:1–14. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
You JH, Wong RS, Waye MM, Mu Y, Lim CK,
Choi KC and Cheng G: Warfarin dosing algorithm using clinical,
demographic and pharmacogenetic data from Chinese patients. J
Thromb Thrombolysis. 31:113–118. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kakkar AK, Mueller I, Bassand JP,
Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY,
Mantovani LG, et al: Risk profiles and antithrombotic treatment of
patients newly diagnosed with atrial fibrillation at risk of
stroke: Perspectives from the international, observational,
prospective GARFIELD registry. PLoS One. 8:e634792013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
International Warfarin Pharmacogenetics
Consortium, ; Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE,
Lee MT, Limdi NA, Page D, Roden DM, et al: Estimation of the
warfarin dose with clinical and pharmacogenetic data. N Engl J Med.
360:753–764. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miao L, Yang J, Huang C and Shen Z:
Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to
the anticoagulant response to warfarin: Proposal for a new dosing
regimen in Chinese patients. Eur J Clin Pharmacol. 63:1135–1141.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang SW, Chen HS, Wang XQ, Huang L, Xu
DL, Hu XJ, Huang ZH, He Y, Chen KM, Xiang DK, et al: Validation of
VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance
dose: A prospective study in Chinese patients. Pharmacogenet
Genomics. 19:226–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhong SL, Yu XY, Liu Y, Xu D, Mai LP, Tan
HH, Lin QX, Yang M and Lin SG: Integrating interacting drugs and
genetic variations to improve the predictability of warfarin
maintenance dose in Chinese patients. Pharmacogenet Genomics.
22:176–182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tan SL, Li Z, Song GB, Liu LM, Zhang W,
Peng J, Zhang T, Jia FF, Zhou G, Zhou HH and Zhou XM: Development
and comparison of a new personalized warfarin stable dose
prediction algorithm in Chinese patients undergoing heart valve
replacement. Pharmazie. 67:930–937. 2012.PubMed/NCBI
|
|
17
|
Chen J, Shao L, Gong L, Luo F, Wang J, Shi
Y, Tan Y, Chen Q, Zhang Y, Hui R and Wang Y: A
pharmacogenetics-based warfarin maintenance dosing algorithm from
Northern Chinese patients. PLoS One. 9:e1052502014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Blanco F, Muriel C, Labrador J,
Gonzalez-Porras JR, Gonzalez-Sarmiento R and Lozano FS: Influence
of UGT2B7, CYP3A4, and OPRM1 gene polymorphisms on transdermal
buprenorphine pain control in patients with critical lower limb
ischemia awaiting revascularization. Pain Pract. 16:842–849. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu R, Zhou ZY, Chen YB, Li JL, Yu WB,
Chen XM, Zhao M, Zhao YQ, Cai YF, Jin J and Huang M: Associations
of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel
resistance in Chinese patients with ischemic stroke. Acta Pharmacol
Sin. 37:882–888. 2016. View Article : Google Scholar : PubMed/NCBI
|
